**To the Editor:** The metallo-β-lactamase (MBL) group of enzymes inactivates many β-lactam antimicrobial drugs. First identified from a *Klebsiella pneumoniae* strain recovered from a patient hospitalized in India, the New Delhi metallo-β-lactamase-1 (NDM-1), particularly in *Enterobacteriaceae*, is now the focus of worldwide attention ([@R1]). Whereas India and Pakistan were considered as the main reservoirs of the *bla*~NDM-1~ gene ([@R2]) that produces this MBL, several NDM-1--producing *Enterobacteriaceae* isolates have been reported from the Balkan states and the Middle East, suggesting that those areas might be secondary reservoirs ([@R2]).

Since 2010, 3 NDM-1 point-mutation variants have been described ([@R3]--[@R5]). The first variant, NDM-2, was identified from an *Acinetobacter baumannii* isolate collected from a patient transferred from a hospital in Egypt to Germany ([@R4]). Subsequently, a clonal dissemination of NDM-2--producing *A. baumanni* was described in Israel ([@R6]). The second variant, NDM-4, which was identified in *Escherichia coli* from a patient hospitalized in India, possessed a higher carbapenemase activity compared with NDM-1 ([@R5]). The most recent variant, NDM-5, was identified in *E. coli* from a patient who had a history of hospitalization in India ([@R3]).

As recommended for the detection of carbapenemase producers ([@R7]), a rectal swab specimen was collected from a patient transferred from Cameroon to France. The *E. coli* strain FEK was isolated from the specimen. He had been hospitalized for 1 month in Douala for an inflammatory syndrome associated with a kidney failure before his transfer to Paris. No history of travel in India was reported for this patient. Susceptibility testing was performed by disk diffusion assay (Sanofi-Diagnostic Pasteur, Marnes-la-Coquette, France), and results were interpreted according to the updated guidelines of the Clinical and Laboratory Standards Institute (Wayne, PA, USA; [www.clsi.org](http://www.clsi.org/)). The MICs were determined by using Etest (bioMérieux, La Balmes-Les-Grottes, France) on Mueller-Hinton agar at 37°C.

*E. coli* FEK was fully resistant to all β-lactam antimicrobial drugs, including imipenem, meropenem, ertapenem, and doripenem (MICs \>32 mg/L for all carbapenems). This isolate was also resistant to aminoglycosides, except amikacin, and to fluoroquinolones. We performed PCR amplification followed by sequencing on whole-cell DNA, as described ([@R8]). We identified the *bla*~NDM-4~, *bla*~CTX-M-15~, and *bla*~OXA-1~ genes. *E. coli* FEK also harbored the *aacA4* gene encoding the AAC(6′)-Ib acetyltransferase that confers high-level resistance to aminoglycosides, except amikacin. Results of multilocus sequence typing analysis performed as described ([@R5]) showed that the isolate belonged to sequence type (ST) ST405. Identification of this ST type among NDM-producing *E. coli*, compared with NDM-4-- and NDM-5--producing *E. coli* in ST648, demonstrated that the spread of NDM-4 occurred among unrelated *E. coli* clonal backgrounds ([@R3],[@R5]).

Plasmid DNA of *E. coli* FEK was extracted and analyzed as described ([@R5]). A single, ≈120-kb plasmid was identified. Direct transfer of the β-lactam resistance marker into *E. coli* J53 was attempted by liquid mating-out assays at 37°C. With the exception of the aminoglycoside amikin, transconjugants from *E. coli* were resistant to β-lactam antimicrobial drugs. MICs of imipenem, meropenem, ertapenem, and doripenem were 6, 3, 6, and 4 mg/L, respectively. The transconjugants harbored an ≈120-kb plasmid carrying *bla*~NDM-4~ and the *bla*~CTX-M-15~, *bla*~OXA-1~, and *aacA4* genes. We performed PCR-based replicon typing as described ([@R5]) and showed that this *bla*~NDM-4~--positive plasmid belonged to the IncFIA incompatibility group. The IncF incompatibility group was previously reported to be associated with *bla*~NDM-4~ and *bla*~NDM-5~ ([@R3],[@R5]).

By analyzing genetic structures surrounding the *bla*~NDM-4~ gene, performed by PCR mapping as described ([@R8]), we identified insertion sequence IS*Aba125* upstream and the bleomycin resistance gene *ble*~MBL~ downstream of the *bla*~NDM-4~ gene. The same genetic environment has been observed for most NDM-1--positive enterobacterial isolates ([@R8]). We showed in previous research that expression of *ble*~MBL~ conferred high-level resistance to bleomycin and bleomycin-like molecules ([@R9]); accordingly, the *E. coli* clinical isolate and its transconjugant were highly resistant to bleomycin (MIC \>512 µg/mL) ([@R9]).

The patient had a history of Hodgkin lymphoma treated by 8 sessions of bleomycin chemotherapy 1 year before his hospitalization. This anticancer drug is widely distributed throughout the body following intravenous administration, and plasmatic concentrations increase in proportion with the increase of the dose ([@R10]). Because the patient was successively treated with 30 mg of bleomycin, the serum levels achieved (≈2--5 mg/mL) might have contributed to selection of the *ble*~MBL~ gene. Similarly, the multiple courses of antibacterial drug therapy administered in Cameroon (including carbapenems) could have contributed to selection of the *bla*~NDM-4~ gene.

By culturing rectal swab samples from the patient, we identified fecal carriage of *E. coli* carrying a plasmid-encoded *bla*~NDM-1~ gene. That strain had a distinct ST type (ST5) compared with the index strain. The plasmid carrying the *bla*~NDM-1~ gene with the *bla*~OXA-1~ and *aacA4* genes belonged to the IncFIA incompatibility group.

β-Lactamase NDM-4 displaying increased carbapenemase activity compared with NDM-1 was described in a patient hospitalized in India ([@R5]). This study shows that NDM-4 producers are also present in Africa; specifically, in the highly populated city of Douala, providing an environment that may promote the dissemination of those strains. We showed that the same patient was carrying strains expressing 2 NDM variants**,** possibly indicating ongoing evolution of NDM variants.
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